Logan Lutton

Here’s what you missed this week on Managed Healthcare Executive.

This number can be attributed to claim denials, high deductibles and the underutilization of digital tools available within plans, according to the 2025 U.S. Commercial Member Health Plan Study from J.D. Power.

A growing trend towards pharmaceutical outpatient treatment spending is driven by accessibility, according to Eric Tichy, Pharm.D., M.B.A., vice chair of pharmacy formulary at the Mayo Clinic Health System.

Almost half (48%) of HIV patients sometimes feel unheard by their healthcare providers, which highlights a need for increased disease awareness, according to the early results of a new ViiV Healthcare survey.

GLP-1s are the main reason why pharmacy expenditures have reached double digits in 2025, a continuing trend from 2024, according to Eric Tichy, Pharm.D., M.B.A., vice chair of pharmacy formulary at the Mayo Clinic Health System.

Eric Tichy, Pharm.D., M.B.A., vice chair of pharmacy formulary at the Mayo Clinic Health System, explains potential pharmaceutical spending trends to inform the budgets of health system leaders.

Here’s what you missed this week on Managed Healthcare Executive.

Zynyz is now FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Self-collected samples to test for cervical cancer are a step in the right direction when it comes to addressing healthcare barriers, according to Rahma S. Mkuu, Ph.D., M.P.H., assistant professor in the Department of Health Outcomes & Biomedical Informatics at the University of Florida College of Medicine.

There are several ways to address HIV in homeless populations, with the most promising being the low barrier care model, according to Julie Dombrowski, M.D., M.P.H., professor of medicine at the University of Washington and director of HIV treatment initiatives at the King County, Seattle public health department.

In a Q&A with Leanne Berge, J.D., CEO of Community Health Plan of Washington, Berge explains what the newly proposed Medicaid bill would mean for enrollees and healthcare systems if passed.

Homelessness and HIV share common risk factors, according to Julie Dombrowski, M.D., M.P.H., professor of medicine at the University of Washington and director of HIV treatment initiatives at the King County, Seattle public health department.

Here’s what you missed this week on Managed Healthcare Executive.

While providers do bring up menopause with patients during visits, there are still some knowledge gaps, according to the results of a recent survey of women ages 40 to 70 and healthcare providers.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

An overview of endometriosis subtypes, treatment options and costs, according to a recent research review published in JAMA.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital and Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.

Here’s what you missed this week on Managed Healthcare Executive.

Children and young adults living in states with the biggest drops in Medicaid coverage experienced more prescription disruptions for their chronic conditions than those living in states with smaller drops, according to a new study by researchers at the University of Michigan.

Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address affordability, access and industry collaboration, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.

Becky Davis of Charles River Associates predicts that an influx of new and oral GLP-1 drugs, along with pricing pressures from policy and competition, will reshape the weight loss drug market in the next two years.

The victims of intimate partner violence were found to have more menopause symptoms, according to the results of a Turkish study published this month in Menopause.

At the 2024 Asembia Specialty Pharmacy Summit, Becky Davis, principal at Charles River Associates, discussed how employer-based insurance coverage for GLP-1s remains uneven—and what factors are influencing decisions about access to these weight-loss treatments.

Fran Gregory, PharmD, MBA, VP of emerging therapies at Cardinal Health, talks about the importance of market access strategies in the cell and gene therapy space.

A future where healthcare may include augmented reality, robots and drones may be more fact than fiction, says George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.

As healthcare AI evolves, there will be a greater emphasis on streamlining administrative tasks, drug production and service delivery, according to George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.

Patients and providers found common ground on the importance of correct billing estimates but did not see eye to eye in terms of digital scheduling tool use, according to a new survey by Experian Health.